Illumina to Announce Third Quarter 2013 Financial Results on Monday, October 21, 2013

  Illumina to Announce Third Quarter 2013 Financial Results on Monday, October
  21, 2013

Business Wire

SAN DIEGO -- October 7, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for
third quarter 2013 following the close of market on Monday, October 21, 2013.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jay Flatley,
President and Chief Executive Officer; Marc Stapley, Senior Vice President and
Chief Financial Officer; and Christian Henry, Senior Vice President and
General Manager, Genomic Solutions, will host a conference call with analysts,
investors, and other interested parties to discuss financial and operating
results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time)
on Monday, October 21, 2013. Interested parties may listen to the call by
dialing 888-680-0869 (passcode: 91263308), or if outside North America, by
dialing +1-617-213-4854 (passcode: 91263308). Individuals may access the live
teleconference in the Investor Relations section of Illumina's web site under
the “Company” tab at www.illumina.com.

A replay of the conference call will be available from 6:00 pm Pacific Time
(9:00 pm Eastern Time) on October 21, 2013 through October 28, 2013 by dialing
888-286-8010 (passcode: 82917243), or if outside North America, by dialing
+1-617-801-6888 (passcode: 82917243).

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA and protein.
We also provide tools and services that are fueling advances in consumer
genomics and diagnostics. Our technology and products accelerate genetic
analysis research and its application, paving the way for molecular medicine
and ultimately transforming healthcare.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com